Background. In patients with congestive heart failure, the chronotropic and inotropic responses to f3-adrenergic agonists are reduced. It is not known whether desensitization of peripheral ,B-adrenoceptors accounts for impaired limb vasodilation in these patients. Accordingly, we studied 14 normal subjects and 13 age-matched patients with congestive heart failure.
Methods and Results. To distinguish vasodilation mediated by 3-adrenoceptors and adenylate cyclase from that mediated by stimulation of guanylate cyclase, each subject received intrabrachial artery infusions of isoproterenol (1-100 ng/min) and sodium nitroprusside (0.3-10 ,ug/min), respectively. Forearm blood flow was determined by venous occlusion plethysmography. Maximal vasodilative potential, determined during reactive hyperemia, was reduced in the patients with congestive heart failure. The maximal forearm blood flow response to isoproterenol was comparable in patients with heart failure and in normal subjects (8.0±+1.1 versus 9.2+1.2 ml/100 ml of tissue/min, respectively, p=NS). Furthermore, the dose-response relation to isoproterenol was similar in both groups. Likewise, the forearm vasodilative response to sodium nitroprusside was preserved in the heart failure group. Plasma concentration of norepinephrine was higher in the patients with heart failure (436+34 versus 201+ 74 pg/ml,p <0.01). When both groups were considered, there was no correlation between norepinephrine levels and the maximal forearm blood flow response to isoproterenol (r=0.10,p=NS).
Conclusions. We conclude that ,-adrenoceptor desensitization does not occur in the limb vessels of patients with congestive heart failure. (Circulation 1991; 83:1873 -1879 In experimental animals and patients with conges- tive heart failure (CHF), the chronotropic and inotropic responses to 83-adrenergic receptor agonists are reduced.1-4 Increased sympathetic nervous system activity has been suggested to reduce ,B-adrenoceptor number or sensitivity. 132-adrenoceptor number is preserved and lymphocyte /32-adrenoceptor density is decreased."1 Accordingly, the purpose of this study was to determine whether the limb vascular response to ,3-adrenoceptor stimulation is impaired in patients with CHF. This information has clinical relevance because it would provide insight as to why limb blood flow is reduced during exercise in these patients. If J82-adrenoceptor function is abnormal in the vessels supplying the skeletal muscles of these individuals, the vasodilative response to increasing catecholamine concentrations during exercise would be blunted, and blood flow augmentation would be attenuated.
Methods

Subjects
The control subject population in this study was made up of 14 During the control period, measurements of forearm blood flow and blood pressure were repeated every 10 minutes until stable. A solution of 5% dextrose was infused intra-arterially at a rate of 0.4 ml/min during this period. To determine the maximal vasodilative potential of the resistance vessels, forearm blood flow was measured in the basal state and during reactive hyperemia after 5 minutes of an ischemic stimulus. Ischemia was induced by inflation of a sphygmomanometric cuff on the upper arm to suprasystolic pressure. Forearm blood flow measurements were repeated until basal conditions were reestablished.
To evaluate ,B-adrenoceptor responsiveness, isoproterenol was infused into the brachial artery. Forearm blood flow was measured during infusion of increasing concentrations of isoproterenol at dosages of 1, 3, 10, 30, and 100 ng/min, each for 5 minutes, delivered at a rate of 0.4 ml/min. Thereafter, 5% dextrose was again infused, and baseline conditions were reestablished. To further evaluate vascular smooth muscle relaxation, each study participant received an intra-arterial infusion of sodium nitroprusside. This agent, which acts directly on vascular smooth muscle to stimulate soluble guanylate cyclase, was given at dosages of 0.03, 0.3, 3, and 10 ,ug/min, at a rate of 0.4 ml/min, each for 5 minutes. Thus, one could distinguish vasodilation mediated by /3-adrenoceptors and adenylate cyclase from that mediated by an agonist that induces vasodilation by activation of guanylate cyclase.
Hemodynamic Measurements
Bilateral forearm blood flow was determined by venous occlusion strain-gauge plethysmography, by use of calibrated mercury-in-Silastic strain gauges, and expressed as milliliters per 100 milliliters of tissue per minute (D.E. Hokansen, Inc., Issaquah, Wash.).12 Each arm was supported above heart level. Venous occlusion pressure averaged 35±5 mm Hg. Circulation to the hand was arrested by inflating a wrist cuff to suprasystolic pressures before each measurement of forearm blood flow. Each forearm blood flow determination comprised at least five separate measurements performed at 10-15-second intervals. By measuring blood flow in the infused arm, one can determine the direct effect of the vasoactive drug. By measuring blood flow in the noninfused arm, one can be assured that systemic effects have not occurred if no changes in blood flow developed during the drug infusion. Forearm vascular resistance was calculated as the ratio of mean blood pressure to forearm blood flow and expressed as units, which reflected millimeters of mercury per milliliter per 100 milliliters of tissue per minute.
Blood pressure was measured by an arterial cannula that was attached to a Statham P23 pressure transducer (Gould-Statham, Oxnard, Calif.), aligned to an amplifier on a Gould physiologic recorder (Gould-Statham). Heart rate was determined from a simultaneously obtained electrocardiographic signal and calculated from the RR interval.
Blood samples for determination of plasma concentrations of norepinephrine and epinephrine were withdrawn after study participants had rested in the supine position for at least 30 minutes after cannula placement. Samples were placed immediately on ice when collected and were centrifuged at 2°C. Plasma samples were stored at -70°C before assays. Plasma concentrations of norepinephrine and epinephrine were quantified by a modified radioenzymatic assay.'3 Statistical Analysis Forearm blood flow, blood pressure, and heart rate data are presented as mean±SEM. All other data are presented as mean±SD. Statistical analysis was performed with analysis of variance of independent groups for repeated measures, followed by NewmanKeuls post hoc testing for statistical significance.14 For nonserial measurements, the Student's t test was used to analyze the difference between the means within each group. The unpaired t test was used to compare the basal conditions between each group. Linear regression analysis was performed for selected hemodynamic variables. Statistical significance was accepted at the 95% confidence level (pc0.05). 
Results
Basal and Reactive Hyperemic Forearm Blood Flow
Basal forearm blood flow in normal subjects and CHF patients were comparable: 2.7 +0.2 and 2.7±0.5 ml/100 ml of tissue/min, respectively (p=NS) ( Figure  1 ). Similarly, forearm vascular resistance at baseline was 36.1+4.3 units in normal subjects and 41.3±4.9 units in CHF patients (p=NS). Reactive hyperemic blood flow, however, was different between the two groups. In normal subjects, it was 23.5 + 1.5 ml/100 ml of tissue/min; in CHF patients, it was significantly less and was 18.7+2.2 ml/100 ml of tissue/min (p<0.05). Minimal vascular resistance determined during reactive hyperemia was 3.6+0.3 and 5.5 +0.7 in normal subjects and in CHF patients, respectively (p<0.05).
Response to Isoproterenol
Mean blood pressure at baseline was 83+4 mm Hg in normal subjects and 89±4 mm Hg in CHF patients (p=NS). Basal heart rate was 61±2 and 78±4 beats/ min in normal subjects and in CHF patients, respectively (p<0.01). The incremental intra-arterial infusion of isoproterenol caused no changes in systemic blood pressure or heart rate in either group.
The forearm blood flow response to isoproterenol in normal subjects and in CHF patients is illustrated in Figure 2 . The maximal forearm blood flow response to isoproterenol in normal subjects was 9.2±1.2 ml/100 ml of tissue/min and in CHF patients was 8.0+1.1 ml/100 ml of tissue/min (p=NS). Fur 
Relation of Plasma Levels of Catecholamines to /3-Adrenoceptor Responsiveness
A rationale for the hypothesis tested in this study was that increased sympathetic nervous system activity, as reflected in high circulating levels of norepinephrine, would depress 8-adrenoceptor sensitivity in CHF patients. Indeed, plasma concentration of norepinephrine in CHF patients was significantly higher than that detected in normal subjects (436±34 versus 201±74 pg/ml, respectively, p<0.01). Plasma concentration of epinephrine was 78+18 and 57+11 The fact that /8-adrenoceptor regulation of limb blood flow is preserved but that ,B-adrenergic effects on heart rate and contractility are reduced may reflect preferential downregulation of I31-receptors by neurally released and circulating norepinephrine. Prior studies examining vasodilator function in patients with heart failure have yielded different conclusions. In the aforementioned report by Zelis et a137 involving CHF patients with peripheral edema, the vasodilative responses to sodium nitrite and phentolamine were attenuated compared with normal subjects. Kubo et al,43 however, reported that the vasodilative responses to phentolamine and yohimbine were preserved in patients with CHF. If an abnormal response to isoproterenol had been detected, we wanted to be certain that this did not reflect a general depression of vascular smooth muscle responsiveness in our CHF patients. For this reason, we measured forearm blood flow during an intra-arterial infusion of sodium nitroprusside, a smooth muscle relaxant that acts by the guanylate cyclase pathway. As was observed with isoproterenol, the forearm vascular response to sodium nitroprusside was similar in both groups.
Exception to these observations can be made in those few patients with the most severe manifestations of CHF. In these patients, generalized impairment occurred during vasodilation, which was reflected in the reduced blood flow responses to reactive hyperemia, nitroprusside, and isoproterenol. Even though plasma norepinephrine concentrations were highest in these individuals, one cannot cite P,2-adrenoceptor downregulation as a cause of the vasodilative dysfunction because catecholamine levels also correlated inversely with reactive hyperemic blood flow and the maximal blood flow responses to nitroprusside. Perhaps a study comprising only patients with end-stage CHF would demonstrate generalized impairment of vasodilation. We believe that the patients enrolled in the study, however, are representative of most patients with CHF.
Conclusions
In these patients with CHF, the forearm blood flow response to reactive hyperemia was impaired, suggesting that structural changes occur in the resistance vessels that limit maximal vasodilation. However, the vasodilative effects of incremental doses of isoproterenol, as well as sodium nitroprusside, were similar to those observed in age-matched normal subjects. We conclude that limb 18-adrenoceptor responsiveness is preserved in patients with CHF.
